P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Oncogenic transformation by vrel requires an amino-terminal activation domain.
TL;DR: The results show that the oncogenicity of Rel proteins requires activation region I and suggest that the biological function of rel and dorsal proteins depends on transcription activation by this region.
Journal ArticleDOI
A genomic analysis of the archaeal system Ignicoccus hospitalis-Nanoarchaeum equitans.
Mircea Podar,Iain Anderson,Kira S. Makarova,James Elkins,Natalia Ivanova,Mark A Wall,Athanasios Lykidis,Kostantinos Mavromatis,Hui Sun,Matthew E. Hudson,Matthew E. Hudson,Wenqiong Chen,Wenqiong Chen,Cosmin Deciu,Don Hutchison,Jonathan R. Eads,Abraham Anderson,Abraham Anderson,Fillipe Fernandes,Ernest Szeto,Alla Lapidus,Nikos C. Kyrpides,Milton H. Saier,Paul G. Richardson,Reinhard Rachel,Harald Huber,Jonathan A. Eisen,Eugene V. Koonin,Martin Keller,Karl O. Stetter +29 more
TL;DR: A combination of genomic and cellular features suggests highly efficient adaptation to the low energy yield of sulfur-hydrogen respiration and efficient inorganic carbon and nitrogen assimilation in hyperthermophiles.
Journal ArticleDOI
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,David Irwin,Edward A. Stadtmauer,Thierry Facon,Jean-Luc Harousseau,Dina Ben-Yehuda,Sagar Lonial,Jesús F. San Miguel,Jamie Cavenagh,Kenneth C. Anderson +11 more
TL;DR: Bortezomib should be considered an appropriate treatment for elderly and high‐risk patients with relapsed multiple myeloma and with >1 prior line of therapy, while rates of serious adverse events were similar; toxicities generally proved manageable.
Journal ArticleDOI
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
Paul G. Richardson,V. Hungria,Sung-Soo Yoon,Meral Beksac,Meletios A. Dimopoulos,Ashraf Elghandour,Wiesław Wiktor Jędrzejczak,Andreas Guenther,Thanyaphong Na Nakorn,Noppadol Siritanaratkul,Robert L. Schlossman,Jian Hou,Philippe Moreau,Sagar Lonial,Jae Hoon Lee,Hermann Einsele,Monika Sopala,Bourras-Rezki Bengoudifa,Claudia Corrado,Florence Binlich,Jesús F. San-Miguel +20 more
TL;DR: This analysis demonstrated a clear PFS benefit of 7.8 months with PAN-BTZ-Dex among patients who received ≥2 prior regimens including bortezomib and an IMiD, a population with limited treatment options and poorer prognosis.
Journal ArticleDOI
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition
Michele Cea,Antonia Cagnetta,Mariateresa Fulciniti,Yu-Tzu Tai,Teru Hideshima,Dharminder Chauhan,Aldo M. Roccaro,Antonio Sacco,Teresa Calimeri,Francesca Cottini,Jana Jakubikova,Sun-Young Kong,Sun-Young Kong,Franco Patrone,Alessio Nencioni,Marco Gobbi,Paul G. Richardson,Nikhil C. Munshi,Kenneth C. Anderson +18 more
TL;DR: A key role of Nampt is defined in MM biology, providing the basis for a novel targeted therapeutic approach, and FK866 triggered cytotoxicity in MM cells resistant to conventional and novel anti-MM therapies and overcomes the protective effects of cytokines and bone marrow stromal cells.